The UK's most complete GLP-1 guide
Every Question Answered. Every Side Effect Explained.
- How GLP-1 medications work
- Mounjaro vs Wegovy compared
- Injection instructions
- Side effects & solutions
- What to eat on treatment
- FAQs answered
Free tracker included with every download this week
How To Avoid Mounjaro Face — Mounjaro vs Wegovy
"Mounjaro face" refers to facial changes some people experience during gradual weight management on tirzepatide medication — including skin sagging, hollowed cheeks, or a gaunt appearance. While this is not a documented side effect in clinical trials, it's a recognised concern among UK users. This guide explains what causes facial changes, how Mounjaro compares to Wegovy, and practical strategies to minimise them. Both medications are prescription-only and require clinical assessment, so discussing your individual risk factors with your prescriber is essential.
10,000+ calculations today · NHS-aligned thresholds · 100% free
Calculate Your BMI Instantly
Enter your height and weight below. Supports both imperial (stone & lbs) and metric (kg). Results include NHS category, healthy weight range, and ethnicity adjustments.
What Is BMI and Why Does It Matter?
Body Mass Index (BMI) is the most widely used screening tool for assessing whether your weight falls within a healthy range. Used by the NHS, GPs, and weight management services across the UK, BMI provides a quick snapshot of your weight relative to your height. The formula is simple: your weight in kilograms divided by your height in metres squared (kg/m²).
While BMI isn't a perfect measure — it doesn't account for muscle mass, bone density, or fat distribution — it remains the standard first step in identifying potential weight-related health risks including type 2 diabetes, cardiovascular disease, high blood pressure, and certain cancers.
The NHS also recommends adjusted thresholds for people of South Asian, Chinese, or Black African heritage — a BMI of 23 or above is classified as overweight, and 27.5 as obese. Our calculator includes this adjustment as a one-click toggle.
Mounjaro vs Wegovy — Mechanism and Weight Loss Differences
Mounjaro (tirzepatide) and Wegovy (semaglutide) work differently, which may influence how quickly you lose weight and potentially affect facial changes. Mounjaro is a dual GIP and GLP-1 receptor agonist, meaning it activates two hormone pathways for appetite control. Wegovy is a GLP-1 agonist only, activating a single pathway. Clinical trial data shows these differences in average weight loss: in the SURMOUNT-1 trial, Mounjaro at maximum dose (15 mg) achieved approximately clinically studied weight loss over 72 weeks. In the STEP-1 trial, Wegovy (semaglutide 2.4 mg) achieved approximately clinically studied weight loss over 68 weeks. gradual weight management — particularly over a short timeframe — is more likely to cause facial volume loss. Both medications are prescribed following a clinical assessment with a UK-licensed prescriber. The Mounjaro UK prescription pathway involves assessing your individual health profile, including your BMI and any weight-related health conditions. Your prescriber can advise on the most suitable dose titration schedule for your circumstances, which may help reduce the pace of facial changes.
Clinically BackedWeight Loss
No appointments. No waiting rooms. Just care — from a UK-regulated online pharmacy.
How It Works
Three simple steps to understand your weight and take action.
Enter your height and weight in our free calculator. Get your BMI, NHS category, healthy weight range, and ethnicity-adjusted thresholds instantly.
If your BMI suggests you're overweight or obese, explore our GLP-1 calculators to project potential weight loss on Mounjaro or Wegovy.
Use our progress tracker to log your weight weekly, visualise your journey with charts, and stay motivated — all stored privately in your browser.
Free Weight Loss Tools & Guides
Everything you need to understand your weight, explore medication options, and track your progress — completely free.
Minimising Facial Changes — Practical Strategies
Facial changes during weight loss occur because fat under the skin (subcutaneous fat) is mobilised for energy, reducing facial volume. Several strategies may help minimise this effect:
- Gradual dose titration: Taking longer between Mounjaro dose increases (staying on each dose 4–6 weeks rather than minimum 4 weeks) can slow weight loss pace.
- Adequate protein intake: Consuming 1.2–1.6g protein per kg body weight may help preserve muscle mass, including facial muscles and supporting structures.
- Hydration: Drinking 2–3 litres of water daily supports skin elasticity and may reduce hollow appearance.
- Skincare and cosmetic support: Dermatologist-recommended moisturisers, retinoids, and (if appropriate) non-invasive treatments like facial fillers can support skin appearance during weight loss.
Use our free GLP-1 weight loss calculator to explore different dose scenarios and projected timelines, which can help you discuss realistic pacing with your prescriber.
- Dual GIP/GLP-1 receptor agonist
- Up to 22.5% body weight loss (SURMOUNT-1)
- Weekly injection, dose escalation over 20+ weeks
- Available via private prescription in the UK
- Doses: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
- GLP-1 receptor agonist
- Up to 15–17% body weight loss (STEP trials)
- Weekly injection, 5-step dose escalation
- NHS & private prescription available
- Doses: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
Mounjaro vs Wegovy: Head-to-Head
A side-by-side comparison of the two most popular GLP-1 weight loss medications available in the UK.
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Active ingredient | Tirzepatide | Semaglutide |
| Avg. weight loss | 15–22.5% | 12–17% |
| Key trial | SURMOUNT-1 (2022) | STEP 1 (2021) |
| Max dose | 15 mg weekly | 2.4 mg weekly |
| Escalation period | 20–32 weeks | 16–20 weeks |
| Administration | Weekly injection (pen) | Weekly injection (pen) |
| NHS availability | Private prescription only | NHS & private |
| Approx. private cost | £150–£250/month | £150–£300/month |
| Common side effects | Nausea, diarrhoea, constipation | Nausea, vomiting, diarrhoea |
Data sourced from SURMOUNT-1 and STEP 1 clinical trials. Costs are approximate and vary by provider. Always consult a prescriber.
Am I Eligible for Weight Loss Medication?
In the UK, eligibility for GLP-1 weight loss medications like Mounjaro and Wegovy is based on your BMI and overall health profile.
- BMI of 30 or above (obese)
- Age 18 or over
- No contraindicated conditions
- Committed to lifestyle changes
- BMI of 27 or above
- Plus type 2 diabetes
- Or high blood pressure
- Or obstructive sleep apnoea
Use our BMI calculator to check whether your BMI falls within the eligible range.
How We Built These Tools
Every calculator and guide on myweightcheck is built with accuracy and transparency in mind. Our BMI calculator uses the standard WHO formula with NHS-aligned category thresholds. Our GLP-1 projections are modelled on published clinical trial data from SURMOUNT and STEP studies.
All data stays on your device. We don't require sign-ups, and we don't store your health information on any server. Your progress tracker saves data locally in your browser using localStorage, so only you can see it.
We're based in the UK and our tools are designed specifically for UK users — supporting stone & lbs by default, referencing NHS guidelines, using NICE-approved medication data, and linking to GPhC-registered pharmacies.
Frequently Asked Questions
Common questions about BMI, weight loss medications, and our free UK tools.
Is "Mounjaro face" a documented side effect?
No. Mounjaro face is not listed as a side effect in clinical trials or the product information. It refers to facial volume loss during gradual weight management, which can occur with any weight loss method. It's a recognised concern rather than a medical side effect specific to tirzepatide.
Does Wegovy cause less facial sagging than Mounjaro?
There is no clinical evidence comparing facial changes between Wegovy and Mounjaro specifically. Both medications cause weight loss, and facial changes depend on the rate and amount of weight lost, not the medication type. Wegovy may result in slightly slower average weight loss, which could theoretically reduce facial changes, but individual variation is significant.
Can I slow down Mounjaro dose increases to avoid facial changes?
Yes. Your prescriber can adjust your Mounjaro dose titration schedule. Standard guidance recommends minimum 4 weeks between dose increases. Taking 6 weeks or longer between increases may slow overall weight loss and reduce the pace of facial changes. Discuss this with your prescriber.
What protein intake helps preserve facial structure during weight loss?
Nutritional evidence suggests consuming 1.2–1.6g of protein per kilogram of ideal body weight daily may help preserve muscle mass during weight loss. For a 70kg person, this means approximately 84–112g protein daily. Higher protein intake (combined with resistance exercise) supports facial muscle tone and skin elasticity.
Should I choose Wegovy over Mounjaro to avoid facial sagging?
Medication choice should be based on individual health assessment, not facial appearance concerns alone. Both require clinical assessment from a UK prescriber, who will consider your BMI, health conditions, and medical history. Discuss your concerns about facial changes when consulting — your prescriber can tailor your treatment plan accordingly.
Ready to take control of your weight loss journey?
Start with a free BMI check, explore your GLP-1 options, or begin tracking your progress today. No sign-up. No cost. Just results.